Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer

J Immunol. 1997 Oct 1;159(7):3113-7.

Abstract

Prostatic acid phosphatase (PAP) is uniquely expressed in prostatic tissue and prostate cancer. In this study, the immunogenicity of PAP was investigated in a male rat model. We show that immunization with recombinant rat or human PAP in CFA leads to a significant Ab response, but does not generate CTL or result in autoimmune prostatitis. In contrast, immunization with recombinant vaccinia expressing human PAP, but not rat PAP, generates a CTL response and tissue-specific prostatitis in the absence of detectable PAP-specific Abs. These findings suggest that a cellular immune response to PAP, rather than Abs, mediates destructive autoimmune prostatitis. Thus, xenogeneic forms of PAP are a new tool for the induction of prostate-specific immunity and may prove useful for the immunotherapy of prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acid Phosphatase / administration & dosage
  • Acid Phosphatase / genetics
  • Acid Phosphatase / immunology*
  • Animals
  • Autoimmune Diseases / enzymology
  • Autoimmune Diseases / etiology*
  • Autoimmune Diseases / therapy*
  • Humans
  • Immunotherapy, Active
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Male
  • Organ Specificity / immunology
  • Prostate / enzymology*
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / immunology*
  • Prostatic Neoplasms / therapy*
  • Prostatitis / enzymology
  • Prostatitis / etiology*
  • Prostatitis / immunology*
  • Rats
  • Rats, Inbred Strains
  • Tumor Cells, Cultured
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / immunology
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology

Substances

  • Vaccines, Synthetic
  • Acid Phosphatase